webcast resource

Development and application of validated immunohistochemical assays for patient selection, pharmacodynamic endpoints in clinical trials

Considerations in assay development and its integration into drug development: Clinical trials and beyond into clinical practice

September 08, 2016 | Length: 28:24 min


Congress:Innovation and Biomarkers in Cancer Drug Development
Presenter:S. Hewitt

Stephen M. Hewitt, M.D., Ph.D., FCAP is a Clinical Investigator within the Laboratory of Pathology, Center for Cancer Research, National Cancer Institute at the National Institutes of Health, in Bethesda Maryland. He is head of the Experimental Pathology Laboratory. Dr. Hewitt’s research interests are in the development of tissue-based biomarkers for cancer diagnosis, prognosis and prediction of response to therapy. Stephen received his B.A. from the Johns Hopkins University, and his Ph.D. from the University of Texas, Graduate School of Biomedical Sciences. He completed his M.D. at the University of Texas Medical School at Houston, and his residency in Anatomic Pathology at the Laboratory of Pathology at the National Cancer Institute. Dr Hewitt has co-authored over 250 articles. Dr. Hewitt is the chair of the Subcommittee on Immunohistochemical Assays for the Clinical Laboratory Standards Institute. He is a consultant to the Hematology and Pathology Devices Panel, Center for Devices and Radiological Health, Food and Drug Administration. Dr. Hewitt is Editor-in-Chief of the Journal of Histochemistry & Cytochemistry.

Category: Cancer;